Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS171 in Autoimmune Diseases
NCT06799520Phase 1Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Interleukins
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of VIS171 in systemic lupus erythematosus (SLE), alopecia areata and focal segmental glomerulosclerosis (FSGS), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Mar 2025; status: active, not recruiting.
02
Drugs
VIS171
03
Conditions
systemic lupus erythematosus (SLE)alopecia areatafocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT06799520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799520.